- Open Access
Prospects for a novel ultrashort pulsed laser technology for pathogen inactivation
© Tsen et al.; licensee BioMed Central Ltd. 2012
- Received: 5 June 2012
- Accepted: 13 June 2012
- Published: 6 July 2012
The threat of emerging pathogens and microbial drug resistance has spurred tremendous efforts to develop new and more effective antimicrobial strategies. Recently, a novel ultrashort pulsed (USP) laser technology has been developed that enables efficient and chemical-free inactivation of a wide spectrum of viral and bacterial pathogens. Such a technology circumvents the need to introduce potentially toxic chemicals and could permit safe and environmentally friendly pathogen reduction, with a multitude of possible applications including the sterilization of pharmaceuticals and blood products, and the generation of attenuated or inactivated vaccines.
- Human Immunodeficiency Virus
- West Nile Virus
- Ultrashort Pulse Laser
- Laser Power Density
- Bovine Serum Albumin Protein
Despite the myriad antimicrobial methods that have been developed to combat infectious disease, microbial pathogens continue to evolve and acquire resistance. In addition, emerging pathogens such as Human Immunodeficiency Virus (HIV)  in the 1980s and more recently West Nile Virus (WNV)  continue to pose threats before testing and containment strategies are in place. Therefore, new and more effective pathogen inactivation strategies are urgently needed.
Use of Ultrashort pulsed (USP) lasers for selective disinfection has emerged as a potentially attractive antimicrobial strategy. USP laser treatment has been shown to inactivate a variety of viruses including HIV, Influenza virus, Human Papillomavirus (HPV), Murine Noroviruses, Hepatitis A Virus (HAV), Encephalomyocarditis Virus (EMCV), Tobacco Mosaic Virus (TMV) and M13 bacteriophage, as well as bacteria such as E. coli Salmonella spp, and Listeria[3–11].
With conventional pharmaceutical antiviral and antibacterial treatments, a new drug is usually required to combat new or mutated strains of microorganisms. In contrast, the USP laser method is effective for the inactivation of enveloped and non-enveloped, single-stranded, double-stranded DNA, RNA viruses, and gram-positive and gram-negative bacteria [3–11], suggesting that the USP laser technique could represent a general method for inactivating viral and bacterial pathogens regardless of their structural composition or mutation status. For the inactivation of a virus, the USP laser method excites mechanical vibrations of the capsid of a virus and targets the weak links of the viral protein coat, leading to its loss of infectivity; for the inactivation of a bacterium, the USP laser technique relaxes the super-coiled double-stranded DNA causing damage and subsequent death of the bacterium. This is demonstrated by the results in Table 1 [3–11] in which a variety of viruses and bacteria have been shown to be efficiently inactivated by the USP lasers.
Existing disinfection methods such as irradiation of ultraviolet (UV) light, gamma-ray, UV/photochemicals, microwave absorption, and pharmaceutical antiviral and antibacterial treatments are not selective; as a result, severe side effects may accompany the treatments. On the other hand, the USP laser method has been shown [3, 6, 9] to inactivate undesired microorganisms like viruses and bacteria while leaving desired materials such as mammalian cells and proteins unharmed; i.e., the USP laser technique is capable of selective disinfection and therefore has minimal potential side effects. Table 2 shows experimental results on the selectivity of a near-infrared USP laser on a variety of microorganisms. The intriguing feature worthwhile mentioning is that there exists a therapeutic window in laser power density between 1 GW/cm2 and 10 GW/cm2 which allows the inactivation of a variety of pathogens while leaving mammalian cells unharmed. The existence of this window enables selective inactivation of microorganisms.
Because of the nature of USP laser inactivation, the USP laser technique is sensitive to the global oscillation of the capsid but not to minor changes caused by nucleic acid mutation in the pathogens; as a result the USP laser technology can be used to inactivate both wild-type and mutated/drug-resistant strains of microorganisms. An example is given for M13 bacteriophages in which both wild-type and engineered strains are efficiently inactivated by the irradiation of USP lasers . This intriguing feature makes the USP laser technique particularly suitable for the disinfection of rapidly evolving or drug-resistant viral and bacterial species such as HIV and MRSA, respectively.
Currently available pathogen reduction methods for blood components usually involve the addition of potentially toxic or carcinogenic chemicals. Residual amounts of these chemicals can remain within the transfusion products and then be transfused. In addition, it is likely that in some cases these chemicals may interact with the product itself, potentially altering its structure or function. The potential side effects due to the introduction of such chemicals during the pathogen reduction process is a major concern from the FDA standpoint  On the other hand, the USP laser technology is chemical-free; in other words, it does not involve introducing chemicals during pathogen reduction. This makes the USP laser method safe and environmentally friendly, and advantageous for treating products such as blood products, pharmaceuticals, therapeutics, vaccines, and other agents that are used in humans.
Killing efficacy for a variety of microorganisms using A 425 nm- femtosecond pulsed laser (laser exposure time = 3.6 seconds)
Human Immunodeficiency Virus (HIV)
Enveloped, single-stranded RNA
Enveloped, single-stranded RNA
Encephalomyocarditis virus (EMCV)
Non-enveloped, single-stranded RNA
Murine norovirus (MNV)
Non-enveloped, single-stranded RNA
Hepatitis A virus (HAV)
Non-enveloped, single-stranded RNA
Human Papillomavirus (HPV)
Non-enveloped, double-stranded DNA
Non-enveloped, single-stranded DNA
Threshold laser power density for inactivation of viruses and cells
Viruses and Cells
Human red blood cell
Human Jurkat T-cell
Mouse dendritic cell
Threshold Laser Power Density for inactivation(GW/cm2)
Inactivation of a virus by ultrashort pulsed lasers
By taking into account the size of small structures about 6 nm in diameter in the AFM images of M13 bacteriophages after USP laser irradiation in Figure 2(b), the resolution of the tip of AFM used in the imaging, and the actual size of the α-helix protein unit which forms the capsid of a M13 bacteriophage, we have found that the small structures observed in Figure 2(b) are consistent in size with those of the α-helix protein units of the capsid of M13 bacteriophages. This analysis further supports our conclusion that USP laser irradiation under our experimental conditions does not damage individual protein units in M13 bacteriophages.
The luminescence, excitation, and circular dichroism (CD) spectra from amino acids of proteins are very sensitive to the structural changes of proteins. Therefore, these optical characterization methods were employed to detect the primary and secondary structural changes of proteins before and after the visible USP laser irradiation. Figures 4(a)4(b)4(c) show our preliminary results for bovine serum albumin (BSA) proteins in buffer solution with and without irradiation with an USP laser . In Figure 4(a), the excitation spectrum corresponded to the broad structure centered around 280 nm. The luminescence spectrum represented the broad peak around 340 nm. Each spectrum contained 4 curves in which two of them were control and two were laser-irradiated samples, as indicated. The two control samples and two laser-irradiated samples had 60 μM, 300μM of BSA proteins, respectively. For clarity, the spectra shown were normalized to the concentration of BSA proteins. In Figure 4(b), the far UV CD contained four curves, in which two of them were control and two were laser-irradiated samples. The two control samples and two laser-irradiated samples had 60μM, 300μM of BSA proteins, respectively. For clarity, the spectra shown were normalized to the concentration of BSA proteins. In Figure 4(c), the near UV CD included four curves in which two of them were control and two were laser-irradiated samples. The two control samples and two laser-irradiated samples had 60 μM, 300 μM of BSA proteins, respectively. For clarity, the spectra shown were normalized to the concentration of BSA proteins. The experimental results show that, within experimental uncertainty, the luminescence, excitation spectra and circular dichroism of BSA proteins remained practically the same before and after the laser irradiation, indicating minimal or no structural changes in BSA proteins after irradiation with a visible USP laser. Therefore, these experimental results on the optical characterization of BSA proteins suggest that there is virtually no structural change in BSA proteins upon USP laser irradiation. Because BSA is primarily made up of α-helix proteins, and the capsid of a M13 bacteriophage is mostly composed of α-helix protein units, these results suggest that the visible USP laser irradiation will not damage the individual protein units that comprise the protein capsid of M13 bacteriophage.
Thus, the AFM images of Figure 2 together with the DNA gel electrophoresis results of Figure 3 and optical results of BSA proteins of Figure 4 are consistent with our model: that irradiation with a USP laser alters the structural integrity of the protein capsid of M13 bacteriophages by disrupting weak interactions between proteins without damaging either the viral genomic single-stranded DNA or the individual protein units of M13 bacteriophage capsid.
Irradiation with an intense ultrashort pulsed laser such as a femtosecond laser can deposit laser energy onto the protein capsid of a viral particle by the excitation of low-frequency acoustic vibrations on the capsid of a virus. This process, known as impulsive stimulated Raman scattering (ISRS), has been used to deposit laser energy to solid state systems as well as to biological molecules [13–20].
The ISRS process can be understood as follows:
where is the angular frequency of vibration, is the damping constant and is the impulsive driving force produced by the excitation laser and is described next.
higher order terms in Q (2); where α0 is the zero order term is the first order term resulting in the first order Raman scattering processes; is the second order term, etc.
Here is the peak intensity of the excitation laser, is the polarizability derivative proportional to the amplitude of the Raman scattering cross section, n is the index of refraction, c the speed of light, and the permittivity of the dielectric medium.
Therefore, in this ISRS process, the deposited laser energy on the protein capsid of a viral particle is proportional to the square of the laser intensity and to the Raman scattering cross section. If the deposited laser energy or the amplitude of the excited resonance mode on the capsid of a viral particle is large enough, it can break the weak links (for example, hydrogen bonds or hydrophobic contacts) between the proteins, damage to the capsid of the virus occurs, leading to the viral inactivation.
In the ISRS process, operated in near-infrared/visible wavelength range to which water is transparent, one way of selective killing of microorganisms is by varying the laser power density; the other way of selective killing of microorganisms in biological systems is by controlling the range of spectral content of an ultrashort pulsed laser. For a transform-limited pulsed laser, by using Heisenberg uncertainty principle, it is equivalent to controlling the laser pulse width. The presence of the factor in Eq. (4) indicates that in order to excited significantly large amplitude of a vibrational frequency in a microorganism for damaging effect, the excitation laser pulse width has to be chosen so that . Because each microorganism has its own characteristic resonance vibrational frequency , by choosing the proper pulse width of an ultrashort pulsed laser, the amplitude of this resonance mode can be excited so high as to damage and inactivate the microorganism.
We note that cw (continuous wave) laser cannot excite the resonance mode of a microorganism through an ISRS process. Because for a cw laser, Eq. (4) therefore indicates that the amplitude of the excited vibrational mode is zero. A Q-switched laser cannot excite the resonance mode of a typical microorganism through ISRS process either. This is because each microorganism has a characteristic resonance vibrational frequency which typically is in the range of 100 GHz;[24–29] for example, helix-shaped M13 bacteriophage is around 300 GHz [27–29] and icosahedral viruses of 30 nm in size like murine norovirus is around 65 GHz  and if we use a viral frequency of 100GHz and the fact that a typical Q-switched laser has a pulse width of about 100 nanosecond, from Eq. (4), the factor becomes vanishingly small. Therefore, the amplitude of vibrations a Q-switched laser will excite is negligibly small.
Dependence of the status of M13 bacteriophage on laser pulse width
Pulse Width (fs)
Spectral Width (cm–1)
Status Inactivation (Yes or No)
Inactivation of bacteria by ultrashort pulsed lasers
Figure 7 demonstrates our preliminary results for isolated double-stranded DNAs in buffer solution before and after irradiation by a visible femtosecond laser, as detected by the agarose gel electrophoresis method . The control sample (labeled No. 1) revealed the presence of three dark bands corresponding to circular, linear, and super-coiled double-stranded DNA, respectively. Sample No. 2 showed that stirring the sample slightly changed the relative darkness of the bands. On the other hand, the laser-irradiated sample (labeled No. 3) showed that the relative darkness of the three bands was greatly altered. These data suggest that the effects of visible femtosecond laser irradiation primarily caused relaxation of the supercoiled double-stranded DNA to produce relaxed circular double-stranded DNA. Because forced changes in the supercoiling status of DNA can disrupt cellular metabolism, which can lead to the death of the cell, one mechanism which can contribute to the inactivation of Salmonella typhimurium by the irradiation of a visible USP laser is relaxation of supercoiled DNA in the bacteria.
In the following sections, we discuss a few of the potential applications we envision for this USP laser technology.
Decontamination of blood products for transfusion
Millions of red blood cell, platelet, plasma and coagulation factor transfusions are performed every year in the United States alone. Implementation of specific donor screening criteria together with nucleic acid and immunologic testing have significantly reduced the risk of transmission of blood components through transfusion for a number of pathogens. This system, however, does not solve all problems posed by pathogens. This is because (1) not all recognized threats have been adequately addressed; (2) there exists a “window period” for a donor during which the infection cannot be detected by testing but during which the donor may be infectious; and (3) screening and tests can only be performed for those pathogens that have been recognized and for which tests are available. Unknown/emerging pathogens will remain as a threat as evidenced by the emergence of HIV and WNV in the past . Therefore, from the transfusion recipient’s viewpoint, the ideal strategy for ensuring transfusion safety of blood components should be to implement a preemptive pathogen reduction (PR) technology, which can universally eliminate microbes in a blood product without chemicals and without adversely affecting the function of the blood product itself. For details of all the currently available PR techniques for the disinfection of blood components, please refer to [37–42]. PR technique in plasma components are dominated by solvent detergent treatment , methylene blue method  and UV-activated photochemical method [45–47] such as using amotosalen and riboflavin. Although these are effective in pathogen reduction, some concerns still exist. Several PR treatments have been developed for platelets. Because these treatments share the use of UV light, although at different wavelengths, possible damage to the blood product and/or microbial resistance becomes a concern. Techniques for PR in red blood cells are largely still under development. A significant concern of the above-mentioned techniques is the addition of foreign chemicals which cannot be completely removed after the treatments. These residual chemicals may have short or long term adverse effects on patients who require frequent transfusion of blood components.
In contrast, the chemical-free USP laser technology has been shown to kill 3–5 log10 of a variety of pathogens (see Table 1), and more importantly, it exhibits selectivity for microbes over desirable proteins and mammalian cells (see Table 2). Therefore, the USP laser technology represents a plausible pathogen inactivation technology for pathogen reduction of blood products.
Sterilization of biologicals and pharmaceuticals
Biologicals and pharmaceuticals used in the clinic as well as reagents or cell cultures used in research laboratories can be contaminated with microbes such as Mycoplasma spp., viruses and bacteria, which can affect their safety profile and their biological function. Traditionally, enveloped viruses or bacteria can be killed by the addition of detergent or alcohol-based chemicals. Non–enveloped viruses are harder to kill and are usually inactivated by either heating or using bleach; however, either the heating process or the addition of such chemicals raises the concern of potential side effects. Filtration is an effective way of removing pathogens; however, it is not applicable when the size of undesired pathogen(s) is comparable to that of the desired product. In these cases, a technique that can non-invasively sterilize a solution containing a desired reagent, cell culture, or pharmaceutical without changing the product’s structure or function is desirable.
In this regard, USP laser technology represents a plausible method for accomplishing sterilization of biologicals, pharmaceuticals, cell cultures, and reagents. Our preliminary results suggest that a visible USP laser can be used to inactivate viral particles and bacteria, without altering the structure of individual protein units . Therefore, USP laser technology could conceivably be useful for sterilizing biologicals, pharmaceuticals, cell cultures, and reagents.
Generation of efficient and safe vaccines
The use of killed or attenuated whole microorganisms is an attractive strategy for the development of immunogenic vaccines for many diseases including tuberculosis and malaria . Whole organism vaccines include most of the relevant antigens and retain many of the immunostimulatory components necessary to induce a strong and specific immune response. Various techniques have been applied to this end, including chemical killing,  UV/psoralen treatment  and gamma-ray irradiation . Chemical methods such as the application of formalin have the advantages of being simple and cost effective; however, it is not as efficient as other methods. Furthermore, the addition of chemicals raises concerns of potential side effects. UV/psoralen treatment has been shown to be promising in generating killed but metabolically active pathogen vaccines in mouse models; however, the added chemicals are very difficult to remove completely. This raises the concern of potential adverse effects when applied in the clinic. Gamma ray irradiation has been demonstrated to be effective in generating inactivated vaccines in mouse models; however, the gamma-ray photon is high-energy ionizing radiation which will break any chemical bonds in its path including covalent, ionic, and hydrogen bonds in the microorganism. As a result, the use of gamma-ray treated vaccines raises concerns that “new chemical species” may be created that may have adverse effects in humans.
We envision that the use of USP lasers to generate whole inactivated vaccines could be advantageous over current methods, partly because the technique kills the organism efficiently with potentially minimal changes to antigenic and/or immunostimulatory structures, [3–10] and partly because no potentially toxic chemicals are added or created. As a matter of fact, our preliminary results (not shown here) with a USP laser-inactivated H1N1 flu vaccine demonstrates vaccine-induced T-cell responses and protection against challenge in a mouse model.
The emergence of drug-resistant microbes and new, heretofore-unknown pathogens has renewed the search for effective antimicrobial technologies. The recently developed USP laser technique for microbial load reduction could represent a universal, non-invasive, and environmentally friendly method for selective inactivation of microbes without the use of clinically toxic or environmentally damaging agents. We predict that the USP laser technology will be used for (1) Decontamination of blood products for transfusion; (2) Sterilization of biologicals, pharmaceuticals, cell cultures, and reagents; and (3) Generation of efficient and safe vaccines in the near future.
The authors would like to thank Stuart M. Lindsay, Sara Vaiana, Chien-Fu Hung, Karen Kibler and Bert Jacobs for their contributions to this line of research. The research was funded by the National Science Foundation. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, or the U.S. Department of Defense.
- Weiss RA: How does HIV cause AIDS?. Science. 1993, 260 (5112): 1273-1279. 10.1126/science.8493571.View ArticlePubMedGoogle Scholar
- Goodnough LT: Risks of blood transfusion. Anesthesiology clinics of North America. 2005, 23 (2): 241-252. 10.1016/j.atc.2004.07.004.View ArticlePubMedGoogle Scholar
- Tsen KT, Tsen S-WD, Fu Q, Lindsay SM, Kibler K, Jacobs B, Wu T-C, Karanam B, Jagu S, Roden R, Hung C-F, Sankey O, Ramakrishna B, Kiang JG: Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J. Biomedical Optics. 2009, 14 (7 pages): 064042-View ArticlePubMedGoogle Scholar
- Tsen KT, Tsen S-WD, Chang C-L, Hung C-F, Wu TC, Kiang JG: Inactivation of viruses by coherent excitations with a low power visible femtosecond Laser. Virology J. 2007, 4 (1–5): 50-View ArticleGoogle Scholar
- Tsen KT, Tsen S-WD, Chang C-L, Hung C-F, Wu TC, Kiang JG: Inactivation of viruses with a very low power visible femtosecond laser. J. Phys: Condensed Matter. 2007, 19 (1–9): 322102-Google Scholar
- Tsen KT, Tsen S-WD, Sankey OF, Kiang JG: Selective inactivation of microorganisms with near-infrared femtosecond laser pulses. J. Phys: Condensed Matter. 2007, 19 (1–7): 472201-Google Scholar
- Tsen KT, Tsen S-WD, Chang C-L, Hung C-F, Wu TC, Kiang JG: Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process. J. Biomedical Optics. 2007, 12 (1–6): 064030-View ArticlePubMedGoogle Scholar
- Tsen KT, Tsen S-WD, Chih-Long C, Chien-Fu H, Wu TC, Ramakrishna B, Mossman K, Kiang JG: Inactivation of viruses with a femtosecond laser via impulsive stimulated Raman scattering. Edited by: Jacques SL, Roach WP, Thomas RJ. 2008, Vol. 6854, 68540NGoogle Scholar
- Tsen S-WD, Tsen Y-SD, Tsen KT, Wu TC: Selective inactivation of viruses with femtosecond laser pulses and its potential use for in vitro therapy. J. Healthcare Engineering. 2010, 1 (2): 185-196. 10.1260/2040-22126.96.36.199.View ArticleGoogle Scholar
- Tsen KT, Tsen S-WD, Fu Q, Lindsay SM, Zhe L, Stephanie C, Sara V, Kiang JG: Studies of inactivation of encephalomyocarditis virus, M13 bacteriophage and Salmonella typhimurium by using a visible femtosecond laser irradiation: Insight into the possible inactivation mechanisms. J. Biomedical Optics. 2011, 16 (1–8): 078003-View ArticlePubMedGoogle Scholar
- Tsen S-W D, Tsen KT: Inactivation of encephalomyocarditis virus and Salmonella typhimurium by using a visible femtosecond laser. Proc. of SPIE on Optical Biopsy IX, Vol. 7895, 78950S. Edited by: Alfano RR, Demos SG. 2011Google Scholar
- Epstein JS, Vostal JG: FDA approach to evaluation of pathogen reduction technology. Transfusion. 2003, 43: 1347-1349. 10.1046/j.1537-2995.2003.00584.x.View ArticlePubMedGoogle Scholar
- Yan Y-X, Jr Gamble EB, Nelson KA: Impulsive stimulated scattering: General importance in femtosecond laser pulse interactions with matter, and spectroscopic applications. J Chem Phys. 1985, 83: 5391-5399. 10.1063/1.449708.View ArticleGoogle Scholar
- Nelson KA, Miller RJD, Lutz DR, Fayer MD: Optical generation of tunable ultrasonic waves. J Appl Phys. 1982, 53: 1144-1149. 10.1063/1.329864.View ArticleGoogle Scholar
- De Silvestri S, Fujimoto JG, Ippen EP, Gamble EB, Williams LR, Nelson KA: Femtosecond time-resolved measurements of optic phonon dephasing by impulsive stimulated raman scattering in α-perylene crystal from 20 to 300 K. Chem Phys Lett. 1985, 116: 146-152. 10.1016/0009-2614(85)80143-3.View ArticleGoogle Scholar
- Nelson KA: Stimulated Brillouin scattering and optical excitation of coherent shear Waves. J Appl Phys. 1982, 53: 6060-6063. 10.1063/1.331556.View ArticleGoogle Scholar
- Cho GC, Kutt W, Kurz H: Subpicosecond time-resolved coherent-phonon oscillations in GaAs. Phys Rev Lett. 1990, 65: 764-766. 10.1103/PhysRevLett.65.764.View ArticlePubMedGoogle Scholar
- Cheng TK, Vidal J, Zeiger HJ, Dresselhaus G, Dresselhaus MS, Ippen EP: Mechanism for displacive excitation of coherent phonons in Sb, Bi, Te, and Ti2O3. Appl Phys Lett. 1991, 59: 1923-1925. 10.1063/1.106187.View ArticleGoogle Scholar
- Chwalek JM, Uher C, Whittaker JF, Mourou GA: Subpicosecond time-resolved studies of coherent phonon oscillations in thin-film YBa2Cu3O6 + x(x < 0.4). Appl Phys Lett. 1991, 58: 980-982. 10.1063/1.104462.View ArticleGoogle Scholar
- Merlin R: Generating coherent THz phonons with light pulses. Solid State Communications. 1997, 102: 207-220. 10.1016/S0038-1098(96)00721-1.View ArticleGoogle Scholar
- Shen YR, Bloembergen N: Theory of simulated Brillouin and Raman scattering. Phys Rev. 1965, 137: A1787-A1805. 10.1103/PhysRev.137.A1787.View ArticleGoogle Scholar
- Shen YR: The Principles of Nonlinear Optics. 1984, Wiley, New YorkGoogle Scholar
- Tsen KT, Tsen S-WD, Dykeman EC, Sankey OF, Kiang JG: Contemporary Trends in Bacteriophage Research. Edited by: Adams HT. 2009, Nova Science Publishers, Inc, , 151-177. ISBN: 978-1-60692-181-4Google Scholar
- Dykeman EC, Sankey OF: Phys. Rev. E. 2010, 81: 021918-View ArticleGoogle Scholar
- Peeters K, Taormina A, Theor J: Biol. 2009, 256: 607-624.Google Scholar
- Janner A: Acta Cryst. 2011, A67: 521-532.View ArticleGoogle Scholar
- Tsen KT, Dykeman EC, Sankey OF, Nien-Tsung L, Tsen S-WD, Kiang JG: Observation of the low frequency vibrational modes of bateriophage M13 in water by Raman spectroscopy. Virology J. 2006, 3 (79): 1-11.Google Scholar
- Tsen S-WD, Lin N-T, Kiang JG, Tsen KT, Dykeman EC, Sankey OF: Raman scattering studies of the low frequency vibrational modes of bacteriophage M13 in water – observation of an axial torsion mode. Nanotechnology. 2006, 17: 5474-5479. 10.1088/0957-4484/17/21/030.View ArticleGoogle Scholar
- Tsen KT, Dykeman EC, Sankey OF: Probing the low frequency vibrational modes of viruses with Raman scattering – bacteriophage M13 in water. J. Biomedical Optics. 2007, 12: 024009-1-014009-6.Google Scholar
- Ashkenazi H, Malik Z, Harth Y, Nitzan Y: Eradication of “Propionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light”. FEMS Immunol Med Microbiol. 2003, 35: 17-24. 10.1111/j.1574-695X.2003.tb00644.x.View ArticlePubMedGoogle Scholar
- Elman MM, Slatkine M, Harth Y: The effective treatment of acne vulgaris by a high-intensity, narrow band 405–420nm light source. J Cosmet Laser Ther. 2003, 5: 111-116. 10.1080/14764170310001276.View ArticlePubMedGoogle Scholar
- Feuerstein O, Persman N, Weiss EI: Phototoxic effect of visible light on Porphyromonas gingivalis and Fusobacterium nucleatum: an in vitro study. Photochem Photobiol. 2004, 80: 412-415.View ArticlePubMedGoogle Scholar
- Ganz RA, Viveiros J, Ahmad A, Ahmadi A, Khalil A, Tolkoff MJ, Nishioka NS, Hamblin MR: Helicobacter pylori in patients can be killed by visible light. Laser Surg Med. 2005, 36: 60-265.View ArticleGoogle Scholar
- Soukos NS, Som S, Abernethy AD, Ruggiero K, Dunham J, Lee C, Doukas AG, Goodson JM: Phototargeting oral blackpigmented Bacteria. Antimicrob Agents Chemother. 2005, 49: 1391-1396. 10.1128/AAC.49.4.1391-1396.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Maclean M, MacGregor SJ, Anderson JG, Woolsey G: High- intensity narrow-spectrum light inactivation and wavelength Sensitivity of Staphylococcus aureus. FEMS Microbiol Lett. 2008, 285: 227-232. 10.1111/j.1574-6968.2008.01233.x.View ArticlePubMedGoogle Scholar
- Bryant J, Klein HG, Pathogen Inactivation, Pathogen Inactivation: The Definitive Safeguard for the Blood Supply. Arch. Pathol. Lab. Med. 2007, 131: 719-733.PubMedGoogle Scholar
- AuBuchon JP: Update on the status of pathogen inactivation methods. ISBT Science Series. 2011, 6: 181-188. 10.1111/j.1751-2824.2011.01471.x.View ArticleGoogle Scholar
- AuBuchon JP: Breathing easy with pathogen inactivation. Blood. 2011, 117: 749-750. 10.1182/blood-2010-11-313379.View ArticlePubMedGoogle Scholar
- Stramer SL, Hollinger FB, Katz LM: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009, 49 (Suppl. 2): 1S-49S.View ArticlePubMedGoogle Scholar
- Prowse C: Properties of pathogen-inactivated plasma components. Transf Med Rev. 2009, 23: 124-133. 10.1016/j.tmrv.2008.12.004.View ArticleGoogle Scholar
- Pelletier JP, Transue S, Snyder EL: Pathogen inactivation techniques. Best Pract Res Clin Haematol. 2006, 19: 205-24242. 10.1016/j.beha.2005.04.001.View ArticlePubMedGoogle Scholar
- Rock G: A comparison of methods of pathogen inactivation of FFP. Vox Sang. 2011, 100: 169-178. 10.1111/j.1423-0410.2010.01374.x.View ArticlePubMedGoogle Scholar
- Horowitz B, Bonomo R, Prince AM: Solvent detergenttreated plasma. A virus-inactivated substitute for fresh frozen plasma. Blood. 1992, 79: 826-833.PubMedGoogle Scholar
- Williamson LM, Cardigan R, Prowse PV: Methylene-blue-treated fresh-frozen plasma: what is its contribution to blood safety. Transfusion. 2003, 43: 1322-1329. 10.1046/j.1537-2995.2003.00483.x.View ArticlePubMedGoogle Scholar
- Larrea L, Calabuig M, Rolda’n V: The influence of riboflavin photochemistry on plasma coagulation factors. Transf Apheresis. 2009, 41: 199-204. 10.1016/j.transci.2009.09.006.View ArticleGoogle Scholar
- Bihm DJ, Ettinger A, Buytaert-Hoefeb KA: Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at −30°C. Vox Sang. 2010, 98: 108-115. 10.1111/j.1423-0410.2009.01238.x.View ArticlePubMedGoogle Scholar
- Smith J, Rock G: Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion. 2010, 50: 926-931. 10.1111/j.1537-2995.2009.02517.x.View ArticlePubMedGoogle Scholar
- Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JYH, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Archie Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW: Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nature Medicine. 2005, 11: 853-860. 10.1038/nm1276.View ArticlePubMedGoogle Scholar
- Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A: Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling. PLoS Pathogens. 2008, 4 (8): e1000138-10.1371/journal.ppat.1000138.PubMed CentralView ArticlePubMedGoogle Scholar
- Alsharifi M, Furuya Y, Bowden TR, Lobigs M, Koskinen A, Regner M, Trinidad L, Boyle DB, Mullbacher A: Intranasal Flu Vaccine Protective against Seasonal and H5N1 Avian Influenza Infections. PLoS One. 2009, 4 (4): e5336-10.1371/journal.pone.0005336.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.